NCT03827837[Secondary Source ID] - Search Results

Your saved search

Your RSS Feed

Page 1

A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma.

Xia L, Zhou Q, Gao Y, Hu W, Lou G, Sun H, Zhu J, Shu J, Zhou X, Sun R, Wu X. Xia L, et al. Nat Commun. 2022 Dec 8;13(1):7581. doi: 10.1038/s41467-022-35133-4. Nat Commun. 2022. PMID: 36481736 Free PMC article. Clinical Trial.

Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study.

Qu YY, Sun Z, Han W, Zou Q, Xing N, Luo H, Zhang X, He C, Bian XJ, Cai J, Chen C, Wang Q, Ye DW. Qu YY, et al. J Immunother Cancer. 2022 May;10(5):e004427. doi: 10.1136/jitc-2021-004427. J Immunother Cancer. 2022. PMID: 35537782 Free PMC article. Clinical Trial.

Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study.

Xia L, Peng J, Lou G, Pan M, Zhou Q, Hu W, Shi H, Wang L, Gao Y, Zhu J, Zhang Y, Sun R, Zhou X, Wang Q, Wu X. Xia L, et al. J Immunother Cancer. 2022 Jan;10(1):e003831. doi: 10.1136/jitc-2021-003831. J Immunother Cancer. 2022. PMID: 35017154 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3 results

Search Page

Filters